Pfizer

Pfizer Oncology Innovation Day Highlights

Accelerate breakthroughs that help people with cancer globally live better and longer lives

Pfizer
175 years of delivering breakthroughs that change patients' lives

Pfizer Oncology

Expertise
Best of both organizations, with exceptional talent and extensive experience

+

Innovation
Robust R&D engine and pipeline, focused on execution and next-generation breakthroughs

+

Scale
New organization with industry leading commercial and manufacturing capabilities

Seagen
Pioneers of ADC technology to improve and extend lives of people with cancer

2030 Oncology Goals

- **2x** patients reached
- **8+** blockbuster medicines
- **~65%** proportion of business from biologics compared to ~6% in 2023

"With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its Oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients. With the energy of our highly talented colleagues, the tremendous potential of our pipeline and scientific engine, and scale of the Pfizer enterprise, we believe we are poised to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives."

Chris Boshoff, MD PhD
Chief Oncology Officer & EVP, Pfizer

Oncology Strategy to Drive Long–Term Sustainable Growth

Modality Focus

Enabled by deep technical expertise

Unique ability to combine and adapt modalities to improve outcomes

- **Small Molecules** — World-class structure-guided drug discovery and medicinal chemistry expertise
- **Antibody-Drug Conjugates (ADCs)** — Next-gen platform aimed at novel targets; improved and differentiated payloads
- **Bispecific Antibodies** — IO biologics leading with bispecific antibodies, leveraging protein engineering and antibody design

Therapeutic Area Focus

Building on established presence

Deepen our ability to address unmet medical needs across care continuum

- **Breast** — Across subtypes
- **Genitourinary** — Prostate Cancer, Urothelial Cancer
- **Hematology - Oncology** — Multiple Myeloma, Lymphoma
- **Thoracic** — Non-Small Cell Lung Cancer, Head & Neck Cancer

Accelerating New Standards of Care

IO, immuno-oncology

Powering Into A New Era Of Oncology Leadership

Key Medicines Today

CD30-DIRECTED ADCETRIS® brentuximab vedotin for injection; IBRANCE® palbociclib 125 mg capsules; Xtandi® (enzalutamide) 40 mg tablets | 80 mg tablets; TALZENNA® talazoparib 1 mg capsules; PADCEV® enfortumab vedotin-ejfv Injection for IV infusion 20 mg & 30 mg vials; LORBRENA® LORLATINIB 100 mg tablets; ELREXFIO™ (elranatamab-bcmm) injection for subcutaneous use 44 mg/1.1 mL, 76 mg/1.9 mL

A Strong Track Record

Expanded Portfolio of Breakthrough Medicines

- **2.3M[2]** Patients treated in 2023
- **PFE +19% revenue CAGR** Oncology Products from 2014 – 2023. Industry average: 10%[1]

Rapidly Delivering Transformational Medicines

- LORBRENA: First in human to approval **4.8 years**
- ELREXFIO: Pivotal start to approval **2.5 years**
- PADCEV: Top-line results to approval **2.8 months**
- **8 approvals** for 8 cancer indications in last 3 years[4]

Accelerating Tomorrow's Breakthroughs

- **49** clinical development programs ongoing
- **>60** discovery programs

Data published by CMR. Fifteen major companies are participating in the Clinical Study Consortium in 2022; this figure was 18 in 2015. Companies in scope are major companies spending greater than $2.0B on R&D. A "top 3" position is considered industry leading for study-level cycle time measures given minor fluctuations in company scores. Industry Best reflects the median values of the top 3 performing companies in the industry.

Deep and Diverse Pipeline Within Focused Therapeutic Areas

	Breast	Genitourinary	Hematology-Oncology	Thoracic
Select approved products	IBRANCE palbociclib; TUKYSA tucatinib	PADCEV enfortumab vedotin-ejfv; Xtandi (enzalutamide); TALZENNA talazoparib + Xtandi (enzalutamide)	ELREXFIO (elranatamab-bcmm); ADCETRIS brentuximab vedotin; Bosulif bosutinib tablets; BESPONSA inotuzumab ozogamicin	LORBRENA LORLATINIB; XALKORI CRIZOTINIB; BRAFTOVI (encorafenib) + MEKTOVI (binimetinib)
Select clinical pipeline	Atirmociclib[5] (CDK4i); Vepdegestrant[5] (PROTAC ER degrader); Felmetatug vedotin[6] (B7H4); Disitamab vedotin[6] (HER2); KAT6i[5] (PF-07248144); CDK2i[5] (PF-07104091)	Sasanlimab[7] (PD-1); Disitamab vedotin[6] (HER2); Mevrometostat[5] (EZH2)	Maplirpacept[7] (CD47 SIRPα); CD70[7] (PF-08046040); CD30[6] (PF-08046045)	Sigvotatug vedotin[6] (IB6); PD-L1[6,10] (PF-08046054); CEACAM5[6] (PF-08046050); EGFR[7,10] (PF-08046052)

Selected preclinical pipeline (FIP anticipated in 2024): STING[5,8], LILRB1/2[7], αLTβR[7,9], mesothelin-TOPO1[6], CD30-TOPO1[6,8]

Key Oncology Catalysts Anticipated Through 1H 2025

Commercial

- **PADCEV** launch LA/mUC (EV-302)
- **XTANDI** launch nmCSPC with high-risk BCR (EMBARK)
- **TALZENNA + XTANDI** launch 1L mCRPC (TALAPRO-2)
- **ELREXFIO** launch TCR MM

Phase 3 Data Readouts

- **Vepdegestrant** 2L ER+ mBC (VERITAC-2)
- **BRAFTOVI** 1L BRAF CRC (BREAKWATER)
- **Sasanlimab** NMIBC (CREST)
- **ELREXFIO** DCE MM (MagnetisMM-5)
- **IBRANCE** HER+ mBC (PATINA)
- **TALZENNA + XTANDI** Overall survival (TALAPRO-2)
- **Disitamab vedotin[11]** 2L+ HER2+/low mUC

Phase 3 Study Starts

- **Atirmociclib** 2L HR+/HER2- mBC ✓
- **Sigvotatug vedotin** 2L-3L NSCLC ✓
- **ELREXFIO** 2L+ post-CD38 MM ✓
- **Mevrometostat + XTANDI** post-abiraterone mCRPC
- **Mevrometostat + XTANDI** treatment-naïve mCRPC
- **Atirmociclib** 1L HR+/HER2- mBC

Early-Stage Pipeline

- **FIP of 8+ NMEs** across small molecules and biologics, including 4 ADCs
- **Key data readouts** PD-L1 and B7H4 ADCs

ADC, antibody-drug conjugate; BCR, biochemical recurrence; CRC, colorectal cancer; DCE, dynamic contrast-enhanced; H, half; HR+, hormone receptor-positive; LA, locally advanced; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; MM, multiple myeloma; mUC, metastatic urothelial carcinoma; nmCSPC, non-metastatic castration-sensitive prostate cancer; NME, new medical entity; NMIBC, non-muscle invasive bladder cancer; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed cell death-ligand 1; TCR, triple class refractory.

Additional Pivotal Readouts Anticipated 2H 2025 and Beyond to Drive Longer-Term Sustainable Growth

Genitourinary	**TALZENNA** HRRm mCSPC	**Mevrometostat** mCRPC post-abi	**Mevrometostat** mCRPC treatment-naïve	**Disitamab vedotin** 1L HER2 mUC	**PADCEV** Cis-eligible MIBC	**PADCEV** Cis-ineligible MIBC
Thoracic	**Sigvotatug vedotin** 2L NSCLC	**Sigvotatug vedotin** 1L NSCLC				
Breast	**TUKYSA** 1L HER+ maint. mBC	**Atirmociclib** 2L HR+ / HER2– mBC	**TUKYSA** HER+ 2L / 3L mBC	**TUKYSA** HER+ adj. BC	**Atirmociclib** 1L ER+ / HER2– mBC	**Vepdegestrant + atirmociclib / IBRANCE** 1L ER+ / HER2– mBC
Hematology-Oncology	**ELREXFIO** 2L+ post-CD38 MM	**ELREXFIO** NDMM PTM	**ELREXFIO** NDMM TI			

Anticipated readouts 2H 2025-2030. Sequence of readouts may differ from slide presentation due to event-driven nature of studies.
Additional potential readout includes TUKYSA® (MOUNTAINEER-03) in 1L HER2+ mCRC.

abi, abiraterone; BC, breast cancer; cis, cisplatin; CRC, colorectal cancer; ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2-positive; HER2–, HER2-negative; HR+, hormone receptor-positive; HRRm, homologous recombination repair mutation; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; MIBC, muscle-invasive bladder cancer; MM, multiple myeloma; mUC, metastatic urothelial carcinoma; NDMM, newly diagnosed multiple myeloma; NHT, novel hormonal therapy; PTM post-transplant maintenance; TI, transplant-ineligible.

Please reference Pfizer's Oncology Innovation Day presentation dated February 29, 2024 and Pfizer's filings with the U.S. Securities and Exchange Commission (SEC) for additional information.

Footnotes:
1. Evaluate Pharma. CAGR, compound annual growth rate.
2. Includes Pfizer Oncology and Pfizer Hospital Unit sterile injectables / cytotoxics; excludes legacy Seagen products. Nearly 1M patients treated with Pfizer Oncology Innovative Medicines and Biosimilars. Patient counts are estimates derived from multiple data sources. Please see the Appendix slide in Pfizer's Oncology Innovation Day presentation for additional information.
3. Working towards achievement of these goals, which are subject to, among other things, clinical trial, regulatory and commercial success and availability of supply.
4. Approved medicines: ELREXFIO™ (NME MM), BRAFTOVI® + MEKTOVI®, TALZENNA®, XTANDI®, ADCETRIS®, PADCEV®, TUKYSA,® and TIVDAK®. CMR, Center for Medicines Research; MM, multiple myeloma; NME, new medical entity.
5. Small molecule
6. Antibody-drug conjugate
7. Immuno-oncology biologic including bispecific antibodies.
8. IND cleared
9. IND submitted
10. Also being explored across multiple solid tumors.
11. Registration-intent Phase 2 trial

Pfizer Oncology Innovation Day Highlights

Appendix

CANCER DISEASE STATISTICS

Cancer remains one of the greatest health challenges of our lifetime

- **~2M** new cancer cases in the US expected in 2024[1]
- **~20M** new cancer cases globally in 2022[2]
- **~10M** deaths from cancer globally in 2022[2], and >600K deaths expected in the US this year[1]

GENITOURINARY CANCERS

Prostate Cancer

- **~299K** estimated new US cases in 2024[1] ; **~35K** estimated US deaths in 2024[1]
- **~$14B** estimated global market size in 2023[3] ; **~$26B** forecasted global market size in 2030[3]

Castration resistant

- 1L metastatic **~51K** US patients[4]
- Non-metastatic **~26K** US patients[4]

Castration sensitive

- Metastatic **~30K** US patients[4]
- Non-metastatic High Risk BCR **~16K** US patients[4]
- TALAPRO-3 study population – epi est US **~8K** HRRm patients[5]

Urothelial Cancer

- **~83K** estimated new US cases in 2024[1] ; **~17K** estimated US deaths in 2024[1]
- **~$5B** estimated global market size in 2023[3] ; **~$17B** forecasted global market size in 2030[3]
- **~18K** US patients with locally advanced/metastatic urothelial cancer (includes bladder cancer)[6]
- **~28K** US patients with muscle invasive bladder cancer[7]
- **~38K** US patients (high risk) with non-muscle invasive bladder cancer[6]

Disitamab vedotin

- **~4K** US patients with 2L HER2+ locally advanced / metastatic urothelial cancer[6]
- **~9K** US patients with 1L HER2+ locally advanced / metastatic urothelial cancer[6]

THORACIC CANCERS

NSCLC

- **~280K** estimated new US cases in 2023[6] ; **~130K** estimated US deaths in 2023[5]
- **~$27B** estimated global market size in 2023[3] ; **~$45B** forecasted global market size in 2030[3]
- B6A-002 study population – estimated US epi **~50K**[9] 2-3L NSCLC

HNSCC

- **~67K** estimated new US cases in 2023[4] ; **~15K** estimated US deaths in 2023[8]
- **~$1.4B** estimated global market size in 2023[3] ; **~$3B** forecasted global market size in 2030[3]

HNSCC breakout[9, 10]

- **~27K** resectable LAD US
- **~18K** unresectable LAD US
- **~16K** 1L US
- **~5.4K** 2L+ US

BREAST CANCER

- **~330K** estimated new US cases in 2023[8] ; **~44K** estimated US deaths in 2023[5]
- **~$30B** estimated global market size in 2023[3] ; **~$60B** forecasted global market size in 2030[3]

Breast Cancer: Collection of Multiple Diseases[11]

- **65% - 70%** HR+ HER2-
- **15 - 20%** HER2+
- **10 - 15%** TNBC

HR+/HER2- [8]

- **~20K** = HR+/HER2- 2L mBC
- **~35K** = HR+/HER2- 1L mBC
- **~220K** = All HR+/HER2- early BC

HER2+ BC[8]

- **~10K** = HER2+ 1L mBC
- **~35K** = All HER2+ early BC

HEMATOLOGY

- Pfizer hematology products reached **~22K+** patients in 2023
- Pfizer's product for cHL has reached more than **~55K** US patients since approval
- More than **2x** increase commercial sales team promoting Pfizer's product for RRMM

Multiple Myeloma

- **~35K** estimated new US cases in 2023[12] ; **~13K** estimated US deaths in 2023[13]
- **~$29B** estimated global market size in 2023[3] **; ~$44B** forecasted global market size in 2030[3]
- US epi **~18K** relapsed/refractory multiple myeloma[14]
- US epi **~31K** newly diagnosed multiple myeloma[14]

PFIZER'S MANUFACTURING FOOTPRINT AND SCALE

Extensive internal network enables agility and supports growth trajectory for additional launches to 2030 and beyond

- **10** manufacturing sites for oncology medicines on three continents
- **6x** increase in ADC vial volume capacity[15]
- **7x** Bioreactors[15]
- **>100** countries

abi, abiraterone; BC, breast cancer; cHL, classical Hodgkin lymphoma; cis, cisplatin; CRC, colorectal cancer; ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2-positive; HER2–, HER2-negative; HR+, hormone receptor-positive; HRRm, homologous recombination repair mutation; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; MIBC, muscle-invasive bladder cancer; MM, multiple myeloma; mUC, metastatic urothelial carcinoma; NDMM, newly diagnosed multiple myeloma; NHT, novel hormonal therapy; PTM post-transplant maintenance; RRMM, relapsed or refractory multiple myeloma; TI, transplant-ineligible.

Please reference Pfizer's Oncology Innovation Day presentation dated February 29, 2024 and Pfizer's filings with the U.S. Securities and Exchange Commission (SEC) for additional information.

Footnotes:

1. American Cancer Society Facts & Figures Report (2024)
2. International Agency for Research on Cancer (IARC) Global Cancer Observatory
3. Clarivate (DRG) Market Forecast (2023)
4. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2024), assuming 25% HRRm frequency
5. SEER
6. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2024)
7. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2024); reflects total miBC population, of which surgery eligible muscle invasive bladder cancer is a sub-population
8. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2023)
9. Pfizer internal analysis
10. Cancer.net. https://www.cancer.net/cancer-types/head-and-neck-cancer/statistics
11. American Cancer Society Breast Cancer Facts & Figures, 2022–2024; Patients within subtypes further categorized based on oncogenic mutations (e.g., BRCA, PIK3CA)
12. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2023). (Total US MM Incidence)
13. US National Cancer Institute, Cancer Stat Facts: Myeloma.
14. Adapted from US CancerMPact Patient Metrics, Cerner Enviza (2023); based on US incidence (symptomatic MM)
15. Compared to Seagen before acquisition